Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice

Cancer Research

Volumn 61, Issue 3, 2001, Pages 970-976

  Zhou, H M ^a   Bolon, I ^a   Nichols, A ^a   Wohlwend, A ^a   Vassalli, J D ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; APOPTOSIS INHIBITOR; KERATIN; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL CELL; CANCER GROWTH; CONTROLLED STUDY; GENE OVEREXPRESSION; INHIBITION KINETICS; KERATINOCYTE; MOUSE; NONHUMAN; PAPILLOMA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TRANSGENIC MOUSE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CELL DIFFERENTIATION; CROSSES, GENETIC; EPIDERMIS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; KERATINOCYTES; MALE; MICE; MICE, INBRED CBA; MICE, TRANSGENIC; PAPILLOMA; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMERASE CHAIN REACTION; RABBITS; SKIN NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035110958     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Biochemical and biological aspects of the plasminogen activation system
2. Plasminogen activator inhibitor-gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
3. Skin abnormalities in mice transgenic for plasminogen activator inhibitor 1: Implications for the regulation of desquamation and follicular neogenesis by plasminogen activator enzymes
4. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937
5. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages
6. Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogan activators inhibitor 2
7. The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb
8. Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4
9. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor α-induced apoptosis. Evidence for an alternative biological function
10. Protection from tumor necrosis-factor mediated cytolysis by over-expression of plasminogen activator inhibitor type 2
11. The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon α/β priming
12. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb
13. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental-type PAI-2
14. Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues
15. Localization of plasminogen activator inhibitor type 2 (PAI-2) in hair and nail: Implications for terminal differentiation
16. Epithelial stem cells in vivo
17. Epidermal stem cells: Markers, patterning and the control of stem cell fate
18. Programmed cell death in terminally differentiating keratinecytes: Role of endogenous endonuclease
19. Plasminogen activator inhibitor type 2: An intracellular keratinecyte differentiation product that is incorporated into the cornified envelope
20. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development
21. Extracellular proteolysis alters tooth development in transgenic mice expressing urokinase-type plasminogen activator in the enamel organ
22. Detection of mRNA in tissue sections using DIG-labeled RNA and oligonucleotide probes
23. Macrophage plasminogen activator: Induction by concanavalin A and phorbol myristate acetate
24. Skin cancer and transgenic mice
25. A secreted serine protease can induce apoptosis in Pam 212 keratinocytes
26. Plasminogen activator inhibitor type-2 in the lesional epidermis of lupus erythematosus
27. The urokinase-type plasminogen activator system in cancer metastasis: A review
28. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions
29. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma
30. Bcl-x expression influences keratinocyte cell survival but not terminal differentiation
31. L transgene promotes malignant conversion of chemically initiated skin papillomas
32. Epidermal tissue homeostasis: Apoptosis and cell emigration as mechanisms of controlled cell deletion in the epidermis of the toad, Bufo bufo
33. Apoptotic cell death induced by intracellular proteolysis
34. Serpins and regulation of cell death
35. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival
36. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures
37. Biochemistry of transglutaminases and cross-linking in the skin
38. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin
39. Biological and clinical aspects of plasminogen activator inhibitor type 2